The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N06 | Psychoanaleptics | |
| 3 | N06B | Psychostimulants, agents used for ADHD and nootropics | |
| 4 | N06BA | Centrally acting sympathomimetics | |
| 5 | N06BA09 | Atomoxetine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 80 mg |
| Active Ingredient | Description | |
|---|---|---|
| Atomoxetine |
Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| INIR Capsule | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| STRATTERA Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
